The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
The endorsement follows overwhelming support for the share swap preceding the merger,
This inspection is now closed
The protections extend through at least 2035, with the potential for further extensions
Marks significant milestone for breakthrough biologic to treat rare blood cancers
The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
